Biodegradable lipid nanoparticles induce a prolonged RNA interference-mediated protein knockdown and show rapid hepatic clearance in mice and nonhuman primates

International Journal of Pharmaceutics

Volumn 519, Issue 1-2, 2017, Pages 34-43

  Suzuki, Yuta ^a   Hyodo, Kenji ^a   Suzuki, Takuya ^a   Tanaka, Yohei ^b   Kikuchi, Hiroshi ^a   Ishihara, Hiroshi ^a  

^a EISAI CO LTD   (Japan)

^b Sogo Pharmaceutical Co Ltd   (Japan)

Author keywords

Biodegradable; Drug delivery; Gene silencing; Lipid nanoparticles; siRNA

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; NANOCARRIER; PROPROTEIN CONVERTASE 9; SMALL INTERFERING RNA; CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN; NANOPARTICLE; OLIGONUCLEOTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIODEGRADABILITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG HYDROLYSIS; DRUG POTENCY; DRUG TARGETING; ENDOCYTOSIS; GENE SILENCING; HEPATIC CLEARANCE; LIVER BIOPSY; LIVER CELL; MACACA FASCICULARIS; MALE; MOUSE; NANOENCAPSULATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PH; PHARMACOGENETICS; PKA; PLASMA HALF LIFE; PRIORITY JOURNAL; RAT; RNA INTERFERENCE; SINGLE DRUG DOSE; SURFACE CHARGE; THERAPEUTIC INDEX; ZETA POTENTIAL; ANIMAL; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; FEMALE; HUMAN; LIVER; METABOLISM; PRIMATE; SPRAGUE DAWLEY RAT;

ANIMALS; CHOLESTEROL; FEMALE; HUMANS; LIPIDS; LIPOPROTEINS, LDL; LIVER; MALE; MICE; MICE, INBRED C57BL; NANOPARTICLES; OLIGONUCLEOTIDES; PRIMATES; PROPROTEIN CONVERTASE 9; RATS; RATS, SPRAGUE-DAWLEY; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 85009228793     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2017.01.016     Document Type: Article

References (32)

1. Akinc, A., Zumbuehl, A., Goldberg, M., Leshchiner, E.S., Busini, V., Hossain, N., Bacallado, S.A., Nguyen, D.N., Fuller, J., Alvarez, R., Borodovsky, A., Borland, T., Constien, R., de Fougerolles, A., Dorkin, J.R., Narayanannair Jayaprakash, K., Jayaraman, M., John, M., Koteliansky, V., Manoharan, M., Nechev, L., Qin, J., Racie, T., Raitcheva, D., Rajeev, K.G., Sah, D.W., Soutschek, J., Toudjarska, I., Vornlocher, H.P., Zimmermann, T.S., Langer, R., Anderson, D.G., A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 26 (2008), 561–569.
2. Allen, T.M., Cullis, P.R., Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65 (2013), 36–48.
3. Barros, S.A., Gollob, J.A., Safety profile of RNAi nanomedicines. Adv. Drug Deliv. Rev. 64 (2012), 1730–1737.
4. Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P.N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., Munisamy, M., Falzone, R., Harrop, J., Cehelsky, J., Bettencourt, B.R., Geissler, M., Butler, J.S., Sehgal, A., Meyers, R.E., Chen, Q., Borland, T., Hutabarat, R.M., Clausen, V.A., Alvarez, R., Fitzgerald, K., Gamba-Vitalo, C., Nochur, S.V., Vaishnaw, A.K., Sah, D.W., Gollob, J.A., Suhr, O.B., Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 369 (2013), 819–829.
5. Davidson, B.L., McCray, P.B. Jr., Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 12 (2011), 329–340.
6. Dong, Y., Love, K.T., Dorkin, J.R., Sirirungruang, S., Zhang, Y., Chen, D., Bogorad, R.L., Yin, H., Chen, Y., Vegas, A.J., Alabi, C.A., Sahay, G., Olejnik, K.T., Wang, W., Schroeder, A., Lytton-Jean, A.K., Siegwart, D.J., Akinc, A., Barnes, C., Barros, S.A., Carioto, M., Fitzgerald, K., Hettinger, J., Kumar, V., Novobrantseva, T.I., Qin, J., Querbes, W., Koteliansky, V., Langer, R., Anderson, D.G., Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 3955–3960.
7. Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., Tuschl, T., Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001), 494–498.
8. Fitzgerald, K., Frank-Kamenetsky, M., Shulga-Morskaya, S., Liebow, A., Bettencourt, B.R., Sutherland, J.E., Hutabarat, R.M., Clausen, V.A., Karsten, V., Cehelsky, J., Nochur, S.V., Kotelianski, V., Horton, J., Mant, T., Chiesa, J., Ritter, J., Munisamy, M., Vaishnaw, A.K., Gollob, J.A., Simon, A., Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383 (2014), 60–68.
9. Haussecker, D., Current issues of RNAi therapeutics delivery and development. J. Control. Release 195 (2014), 49–54.
10. Heyes, J., Palmer, L., Bremner, K., MacLachlan, I., Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J. Control. Release 107 (2005), 276–287.
11. Jayaraman, M., Ansell, S.M., Mui, B.L., Tam, Y.K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J.K., Rajeev, K.G., Hafez, I.M., Akinc, A., Maier, M.A., Tracy, M.A., Cullis, P.R., Madden, T.D., Manoharan, M., Hope, M.J., Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. Int. Ed. Engl. 51 (2012), 8529–8533.
12. Jere, D., Jiang, H.L., Arote, R., Kim, Y.K., Choi, Y.J., Cho, M.H., Akaike, T., Cho, C.S., Degradable polyethylenimines as DNA and small interfering RNA carriers. Expert Opin. Drug Deliv. 6 (2009), 827–834.
13. Judge, A.D., Robbins, M., Tavakoli, I., Levi, J., Hu, L., Fronda, A., Ambegia, E., McClintock, K., MacLachlan, I., Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J. Clin. Invest. 119 (2009), 661–673.
14. Kel In, A.V., Zlatev, I., Harp, J., Jayaraman, M., Bisbe, A., O'Shea, J., Taneja, N., Manoharan, R.M., Khan, S., Charisse, K., Maier, M.A., Egli, M., Rajeev, K.G., Manoharan, M., Structural basis of duplex thermodynamic stability and enhanced nuclease resistance of 5'-C-methyl pyrimidine-modified oligonucleotides. J. Org. Chem. 81 (2016), 2261–2279.
15. Love, K.T., Mahon, K.P., Levins, C.G., Whitehead, K.A., Querbes, W., Dorkin, J.R., Qin, J., Cantley, W., Qin, L.L., Racie, T., Frank-Kamenetsky, M., Yip, K.N., Alvarez, R., Sah, D.W., de Fougerolles, A., Fitzgerald, K., Koteliansky, V., Akinc, A., Langer, R., Anderson, D.G., Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 1864–1869.
16. Luten, J., van Nostrum, C.F., De Smedt, S.C., Hennink, W.E., Biodegradable polymers as non-viral carriers for plasmid DNA delivery. J. Control. Release 126 (2008), 97–110.
17. Maier, M.A., Jayaraman, M., Matsuda, S., Liu, J., Barros, S., Querbes, W., Tam, Y.K., Ansell, S.M., Kumar, V., Qin, J., Zhang, X., Wang, Q., Panesar, S., Hutabarat, R., Carioto, M., Hettinger, J., Kandasamy, P., Butler, D., Rajeev, K.G., Pang, B., Charisse, K., Fitzgerald, K., Mui, B.L., Du, X., Cullis, P., Madden, T.D., Hope, M.J., Manoharan, M., Akinc, A., Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol. Ther. 21 (2013), 1570–1578.
18. Sato, Y., Hatakeyama, H., Sakurai, Y., Hyodo, M., Akita, H., Harashima, H., A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo. J. Control. Release 163 (2012), 267–276.
19. Semple, S.C., Akinc, A., Chen, J., Sandhu, A.P., Mui, B.L., Cho, C.K., Sah, D.W., Stebbing, D., Crosley, E.J., Yaworski, E., Hafez, I.M., Dorkin, J.R., Qin, J., Lam, K., Rajeev, K.G., Wong, K.F., Jeffs, L.B., Nechev, L., Eisenhardt, M.L., Jayaraman, M., Kazem, M., Maier, M.A., Srinivasulu, M., Weinstein, M.J., Chen, Q., Alvarez, R., Barros, S.A., De, S., Klimuk, S.K., Borland, T., Kosovrasti, V., Cantley, W.L., Tam, Y.K., Manoharan, M., Ciufolini, M.A., Tracy, M.A., de Fougerolles, A., MacLachlan, I., Cullis, P.R., Madden, T.D., Hope, M.J., Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28 (2010), 172–176.
20. Shi, B., Abrams, M., Technologies for investigating the physiological barriers to efficient lipid nanoparticle-siRNA delivery. J. Histochem. Cytochem. 61 (2013), 407–420.
21. Suzuki, Y., Ishihara, H., Structure, activity and uptake mechanism of siRNA-lipid nanoparticles with an asymmetric ionizable lipid. Int. J. Pharm. 510 (2016), 350–358.
22. Suzuki, Y., Hyodo, K., Tanaka, Y., Ishihara, H., siRNA-lipid nanoparticles with long-term storage stability facilitate potent gene-silencing in vivo. J. Control. Release 220 (2015), 44–50.
23. Testa, B., Mayer, J.M., The hydrolysis of carboxylic acid ester prodrugs. Hydrolysis in Drug and Prodrug Metabolism, 2006, Verlag Helvetica Chimica Acta, 419–534.
24. Vons, C., Beaudoin, S., Helmy, N., Dagher, I., Weber, A., Franco, D., First description of the surgical anatomy of the cynomolgus monkey liver. Am. J. Primatol. 71 (2009), 400–408.
25. Walsh, C., Ou, K., Belliveau, N.M., Leaver, T.J., Wild, A.W., Huft, J., Lin, P.J., Chen, S., Leung, A.K., Lee, J.B., Hansen, C.L., Taylor, R.J., Ramsay, E.C., Cullis, P.R., Microfluidic-based manufacture of siRNA-lipid nanoparticles for therapeutic applications. Methods Mol. Biol. 1141 (2014), 109–120.
26. Whitehead, K.A., Langer, R., Anderson, D.G., Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8 (2009), 129–138.
27. Whitehead, K.A., Dorkin, J.R., Vegas, A.J., Chang, P.H., Veiseh, O., Matthews, J., Fenton, O.S., Zhang, Y., Olejnik, K.T., Yesilyurt, V., Chen, D., Barros, S., Klebanov, B., Novobrantseva, T., Langer, R., Anderson, D.G., Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nat. Commun., 5, 2014, 4277.
28. Wittrup, A., Ai, A., Liu, X., Hamar, P., Trifonova, R., Charisse, K., Manoharan, M., Kirchhausen, T., Lieberman, J., Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown. Nat. Biotechnol. 33 (2015), 870–876.
29. Yin, W., Carballo-Jane, E., McLaren, D.G., Mendoza, V.H., Gagen, K., Geoghagen, N.S., McNamara, L.A., Gorski, J.N., Eiermann, G.J., Petrov, A., Wolff, M., Tong, X., Wilsie, L.C., Akiyama, T.E., Chen, J., Thankappan, A., Xue, J., Ping, X., Andrews, G., Wickham, L.A., Gai, C.L., Trinh, T., Kulick, A.A., Donnelly, M.J., Voronin, G.O., Rosa, R., Cumiskey, A.M., Bekkari, K., Mitnaul, L.J., Puig, O., Chen, F., Raubertas, R., Wong, P.H., Hansen, B.C., Koblan, K.S., Roddy, T.P., Hubbard, B.K., Strack, A.M., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J. Lipid Res. 53 (2012), 51–65.
30. Zhou, K., Nguyen, L.H., Miller, J.B., Yan, Y., Kos, P., Xiong, H., Li, L., Hao, J., Minnig, J.T., Zhu, H., Siegwart, D.J., Modular degradable dendrimers enable small RNAs to extend survival in an aggressive liver cancer model. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), 520–525.
31. Zimmermann, T.S., Lee, A.C., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M.N., Harborth, J., Heyes, J.A., Jeffs, L.B., John, M., Judge, A.D., Lam, K., McClintock, K., Nechev, L.V., Palmer, L.R., Racie, T., Rohl, I., Seiffert, S., Shanmugam, S., Sood, V., Soutschek, J., Toudjarska, I., Wheat, A.J., Yaworski, E., Zedalis, W., Koteliansky, V., Manoharan, M., Vornlocher, H.P., MacLachlan, I., RNAi-mediated gene silencing in non-human primates. Nature 441 (2006), 111–114.
32. Zuckerman, J.E., Davis, M.E., Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat. Rev. Drug Discov. 14 (2015), 843–856.